Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William D Figg

Showing results (21-30 of 638) with videos related to

Pageof 64
Sort By:
Cancer Biology & Therapy|June 16, 2004
Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockadeGordon R Macpherson, William D Figg
Cancer Biology & Therapy|January 11, 2005
Immunomodulation of multiple myelomaTanyifor M Tohnya, William D Figg
The Lancet. Oncology|January 2, 2021
Facebook groups for alternative treatments for cancer: advertising masquerading as community supportTristan M Sissung, William D Figg
Translational Cancer Research|January 8, 2019
The potential role of curcumin in prostate cancer: the importance of optimizing pharmacokinetics in clinical studiesKeith T Schmidt, William D Figg
Nature Reviews. Urology|May 10, 2018
Revisiting 5α-reductase inhibitors and the risk of prostate cancerCindy H Chau, William D Figg
JAMA Oncology|July 17, 2015
Effect of 5α-Reductase Inhibitor Use on Mortality From Prostate CancerWilliam D Figg, Ian M Thompson
Nature Reviews. Cancer|June 24, 2006
Drug interactions in cancer therapyCharity D Scripture, William D Figg
Cancer Biology & Therapy|September 14, 2006
Lysyl oxidase (LOX) and hypoxia-induced metastasesAmy M Sion, William D Figg
Pharmacotherapy|November 19, 2003
Pharmacy education: back to the basics?William D Figg, Michael C Cox
Anticancer Research|December 12, 2003
Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient miceSylvia S Ng, William D Figg
Pageof 64

Showing results (21-30 of 638) with videos related to

Sort By:
Pageof 64
Cancer Biology & Therapy|June 16, 2004
Small molecule-mediated anti-cancer therapy via hypoxia-inducible factor-1 blockadeGordon R Macpherson, William D Figg
Cancer Biology & Therapy|January 11, 2005
Immunomodulation of multiple myelomaTanyifor M Tohnya, William D Figg
The Lancet. Oncology|January 2, 2021
Facebook groups for alternative treatments for cancer: advertising masquerading as community supportTristan M Sissung, William D Figg
Translational Cancer Research|January 8, 2019
The potential role of curcumin in prostate cancer: the importance of optimizing pharmacokinetics in clinical studiesKeith T Schmidt, William D Figg
Nature Reviews. Urology|May 10, 2018
Revisiting 5α-reductase inhibitors and the risk of prostate cancerCindy H Chau, William D Figg
JAMA Oncology|July 17, 2015
Effect of 5α-Reductase Inhibitor Use on Mortality From Prostate CancerWilliam D Figg, Ian M Thompson
Nature Reviews. Cancer|June 24, 2006
Drug interactions in cancer therapyCharity D Scripture, William D Figg
Cancer Biology & Therapy|September 14, 2006
Lysyl oxidase (LOX) and hypoxia-induced metastasesAmy M Sion, William D Figg
Pharmacotherapy|November 19, 2003
Pharmacy education: back to the basics?William D Figg, Michael C Cox
Anticancer Research|December 12, 2003
Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient miceSylvia S Ng, William D Figg
Pageof 64